Intellia Therapeutics Inc (NTLA) is scheduled to report 3rd quarter earnings on 10/31/2024. Regarding Q3 estimates, Wall Street analysts expect Intellia Therapeutics Inc to post earnings of -$1.39 per share.
Intellia Therapeutics Inc (NTLA) is scheduled to report 3rd quarter earnings on 10/31/2024. Regarding Q3 estimates, Wall Street analysts expect Intellia Therapeutics Inc to post earnings of -$1.39 per share.
Intellia Therapeutics ( ($NTLA) ) has provided an announcement. Intellia Therapeutics has announced promising Phase 2 results for NTLA-2002, a CRISPR-based gene editing therapy aimed at treating hereditary angioedema (HAE).
Citi analyst David Lebowitz lowered the firm’s price target on Intellia Therapeutics (NTLA) to $19 from $25 and keeps a Neutral rating on the shares after the company presented detailed
David Lebowitz, an analyst from Citi, maintained the Hold rating on Intellia Therapeutics (NTLA – Research Report). The associated price target is $19.00. David Lebowitz has given his Hold rating